Angiogenesis in metabolic-vascular disease

Summary

Angiogenesis, literally formation of new blood vessels, is the main process through which the vascular system expands during embryonic and postnatal development. Endothelial cells, which constitute the inner lining of all blood vessels, are typically in a quiescent state in the healthy adult organism. However, in vascular and metabolic diseases, the endothelium becomes unstable and dysfunctional. The resulting tissue hypoxia may thereby induce pathological angiogenesis, which is a hallmark of disease conditions like cancer or diabetic retinopathy. However, recent evidence suggests that angiogenesis is also a major player in the context of further metabolic diseases, especially in obesity. In particular, deregulated angiogenesis is linked with adipose tissue dysfunction and insulin resistance. On the other hand, signalling pathways, such as the PI3K pathway, may regulate metabolic activities in the endothelium. Endothelial cell metabolism emerges as an important regulator of angiogenesis. This review summarises the role of angiogenesis in metabolic-vascular disease, with specific focus on the role of angiogenesis in obesity-related metabolic dysfunction and on signaling pathways, especially PI3K, linking cell metabolism to endothelial function.

Keywords

Angiogenesis - diabetes - obesity - PI3-kinase - insulin resistance - metabolism - glycolysis

^* All authors contributed equally to the work.

• References

• 1 Carmeliet P. Angiogenesis in health and disease. Nature Med 2003; 9: 653-660.
• 2 Dejana E. et al. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Develop Cell 2009; 16: 209-221.
• 3 Gerhardt H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163-1177.
• 4 Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69 (Suppl. 03) 11-16.
• 5 Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nature Rev Drug Discov 2011; 10: 417-427.
• 6 Ebneter A, Zinkernagel MS. Novelties in Diabetic Retinopathy. Endocr Develop 2016; 31: 84-96.
• 7 Armulik A. et al. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Develop Cell 2011; 21: 193-215.
• 8 Eelen G. et al. Endothelial cell metabolism in normal and diseased vasculature. Circ Res 2015; 116: 1231-1244.
• 9 Chmelar J. et al. The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance. Thromb Haemost 2013; 109: 399-406.
• 10 Crewe C. et al. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest 2017; 127: 74-82.
• 11 Alexaki VI, Chavakis T. The role of innate immunity in the regulation of brown and beige adipogenesis. Rev Endocr Metab Disord 2016; 17: 41-49.
• 12 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556.
• 13 Rabe K. et al. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
• 14 Cohen P, Spiegelman BM. Cell biology of fat storage. Mol Biol Cell 2016; 27: 2523-2527.
• 15 Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nature Med 2013; 19: 1252-1263.
• 16 Wu J. et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012; 150: 366-376.
• 17 Fromme T, Klingenspor M. Uncoupling protein 1 expression and high-fat diets. Am J Physiol Regul Integr Comp Physiol 2011; 300: R1-R8.
• 18 Shimizu I. et al. Vascular rarefaction mediates whitening of brown fat in obesity. J Clin Invest 2014; 124: 2099-2112.
• 19 Cypess AM. et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009; 360: 1509-1517.
• 20 Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest 2017; 127: 1-4.
• 21 McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity 2014; 41: 36-48.
• 22 Chatzigeorgiou A. et al. Lymphocytes in obesity-related adipose tissue inflammation. Diabetologia 2012; 55: 2583-2592.
• 23 Brestoff JR. et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 2015; 519: 242-246.
• 24 Lee MW. et al. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell 2015; 160: 74-87.
• 25 Qiu Y. et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 2014; 157: 1292-1308.
• 26 Wu D. et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011; 332: 243-247.
• 27 Chung KJ. et al. A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity. Nat Immunol 2017; 18: 654-664.
• 28 Shan B. et al. The metabolic ER stress sensor IRE1alpha suppresses alternative activation of macrophages and impairs energy expenditure in obesity. Nat Immunol 2017; 18: 519.
• 29 Cao Y. Angiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivity. Cell Metab 2013; 18: 478-489.
• 30 Lemoine AY. et al. Adipose tissue angiogenesis in obesity. Thromb Haemost 2013; 110: 661-668.
• 31 Gealekman O. et al. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation 2011; 123: 186-194.
• 32 Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 2007; 117: 2362-2368.
• 33 Garcia-Martin R. et al. Adipocyte-Specific Hypoxia-Inducible Factor 2alpha Deficiency Exacerbates Obesity-Induced Brown Adipose Tissue Dysfunction and Metabolic Dysregulation. Mol Cell Biol 2016; 36: 376-393.
• 34 Sung HK. et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab 2013; 17: 61-72.
• 35 Pasarica M. et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009; 58: 718-725.
• 36 Ngo DT. et al. Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation 2014; 130: 1072-1080.
• 37 Karki S, Ngo D, Farb MG. et al. WNT5A Regulates Adipose Tissue Angiogenesis via Anti-Angiogenic VEGFA165b in Obese Humans. Am J Physiol Heart Circ Physiol 2017 ; Epub ahead of print.
• 38 Elias I. et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012; 61: 1801-1813.
• 39 Michailidou Z. et al. Increased angiogenesis protects against adipose hypoxia and fibrosis in metabolic disease-resistant 11beta-hydroxysteroid dehydrogenase type 1 (HSD1)-deficient mice. J Biol Chem 2012; 287: 4188-4197.
• 40 Robciuc MR. et al. VEGFB/VEGFR1-Induced Expansion of Adipose Vasculature Counteracts Obesity and Related Metabolic Complications. Cell Metab 2016; 23: 712-724.
• 41 Seki T. et al. Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat. Nat Commun 2016; 7: 12152.
• 42 Gealekman O. et al. Control of adipose tissue expandability in response to high fat diet by the insulin-like growth factor-binding protein-4. J Biol Chem 2014; 289: 18327-18338.
• 43 An YA, Sun K, Joffin N. et al. Angiopoietin-2 in white adipose tissue improves metabolic homeostasis through enhanced angiogenesis. Elife 2017; ; 6.
• 44 Xue Y. et al. FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc Natl Acad Sci USA 2008; 105: 10167-10172.
• 45 Zhang X. et al. Adipose tissue-specific inhibition of hypoxia-inducible factor 1{alpha} induces obesity and glucose intolerance by impeding energy expenditure in mice. J Biol Chem 2010; 285: 32869-32877.
• 46 Tang W. et al. White fat progenitor cells reside in the adipose vasculature. Science 2008; 322: 583-586.
• 47 Gupta RK. et al. Transcriptional control of preadipocyte determination by Zfp423. Nature 2010; 464: 619-623.
• 48 Gupta RK. et al. Zfp423 expression identifies committed preadipocytes and localizes to adipose endothelial and perivascular cells. Cell Metab 2012; 15: 230-239.
• 49 Wu LE. et al. Systemic VEGF-A neutralization ameliorates diet-induced metabolic dysfunction. Diabetes 2014; 63: 2656-2667.
• 50 Brakenhielm E. et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circulation Res 2004; 94: 1579-1588.
• 51 Xue Y. et al. Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles. Proc Natl Acad Sci USA 2016; 113: 5552-5557.
• 52 Graupera M, Potente M. Regulation of angiogenesis by PI3K signaling networks. Experim Cell Res 2013; 319: 1348-1355.
• 53 Hirsch E. et al. PI3K in cancer-stroma interactions: bad in seed and ugly in soil. Oncogene 2014; 33: 3083-3090.
• 54 Piecewicz SM. et al. Insulin-like growth factors promote vasculogenesis in embryonic stem cells. PloS one 2012; 7: e32191.
• 55 Graupera M. et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453: 662-666.
• 56 Heller R. et al. Overlapping and distinct roles for PI3Kbeta and gamma isoforms in S1P-induced migration of human and mouse endothelial cells. Cardiovasc Res 2008; 80: 96-105.
• 57 Madeddu P. et al. Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Arterioscl Thromb Vasc Biol 2008; 28: 68-76.
• 58 Kaneda MM. et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature 2016; 539: 437-442.
• 59 Yoshioka K. et al. Endothelial PI3K-C2alpha, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nature Med 2012; 18: 1560-1569.
• 60 Franco I. et al. PI3K class II alpha controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. Develop Cell 2014; 28: 647-658.
• 61 Castel P. et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Science Transl Med 2016; 8: 332ra42.
• 62 Castillo SD. et al. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Science Transl Med 2016; 8: 332ra43.
• 63 Osborn AJ. et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. Human Mol Gen 2015; 24: 926-938.
• 64 Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell 2017; 168: 960-976.
• 65 Potente M, Carmeliet P. The Link Between Angiogenesis and Endothelial Metabolism. Ann Rev Physiol 2017; 79: 43-66.
• 66 Vander Heiden MG. et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
• 67 Vizan P. et al. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis 2009; 30: 946-952.
• 68 Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab 2016; 23: 27-47.
• 69 Ziegler ME. et al. mTORC2 mediates CXCL12-induced angiogenesis. Angiogenesis 2016; 19: 359-371.
• 70 Farhan MA. et al. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis. PloS one 2015; 10: e0135245.
• 71 Wang S. et al. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways. Mol Cell Biol 2015; 35: 1299-1313.
• 72 Gerber HP. et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
• 73 Tsuji-Tamura K, Ogawa M. Inhibition of the PI3K-Akt and mTORC1 signaling pathways promotes the elongation of vascular endothelial cells. J Cell Sci 2016; 129: 1165-1178.
• 74 Wilhelm K. et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature 2016; 529: 216-220.
• 75 Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
• 76 Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 2009; 120: 1266-1286.
• 77 Sasaki N. et al. Augmentation of vascular remodeling by uncoupled endothelial nitric oxide synthase in a mouse model of diabetes mellitus. Arterioscl Thromb Vasc Biol 2008; 28: 1068-1076.
• 78 Stirban A. et al. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab 2014; 3: 94-108.
• 79 Chavakis T. et al. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004; 6: 1219-1225.
• 80 Chavakis T. et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1507-1515.
• 81 Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circulation Res 2010; 107: 1058-1070.
• 82 Nishikawa T. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
• 83 Dimmeler S. et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605.
• 84 Escudero CA, Herlitz K, Troncoso F. et al. Pro-angiogenic Role of Insulin: From Physiology to Pathology. Front Physiol 2017; 8: 204.
• 85 Rask-Madsen C. et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab 2010; 11: 379-389.
• 86 Kubota T. et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011; 13: 294-307.
• 87 Perticone F. et al. Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 2004; 89: 3606-3609.
• 88 Federici M. et al. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 2004; 109: 399-405.
• 89 Soler A. et al. PI3K at the crossroads of tumor angiogenesis signaling pathways. Mol Cell Oncol 2015; 2: e975624.
• 90 Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
• 91 Economopoulou M. et al. Endothelial-specific deficiency of Junctional Adhesion Molecule-C promotes vessel normalisation in proliferative retinopathy. Thromb Haemost 2015; 114: 1241-1249.
• 92 Treps L. et al. Manipulating Angiogenesis by Targeting Endothelial Metabolism: Hitting the Engine Rather than the Drivers-A New Perspective?. Pharmacol Rev 2016; 68: 872-887.